The Arkansas Insurance Department (AID) has formally notified at least four drugmakers that they are in potential violation of a [...] …
Month: August 2023
Congress is unlikely to clear any major reform of the 340B in the remaining months of 2023, unless spurred by [...] …
SPONSORED CONTENT
As the complexity of managing 340B programs continues to increase, there is a growing need for advanced tools and technologies to ensure compliance integrity and optimize financial stewardship. In this article, we’ll explore the scope of analytics and artificial intelligence
…
The Health Resources and Services Administration (HRSA) has awarded a $25.3 million, five-year contract to The Bizzell Group to audit [...] …
Drug maker Boehringer Ingelheim (BI) sued the federal government to block Medicare price negotiations shortly before the Department of Health [...] …
SPONSORED CONTENT
TIP: Make sure you keep an eye on your prescriber lists.
As one of the
Recent apparent changes to 340B drug pricing conditions by drug manufacturer Sanofi may eliminate 340B discounts for health centers using [...] …
The congressional sponsor of legislation that would require hospitals and potentially other covered entities to publicly report their 340B revenue, [...] …
SPONSORED CONTENT
When a covered entity enrolls in the 340B program it must inform the Health Resources and Services Administration (HRSA) whether it will “carve in” and acquire 340B drugs for its Medicaid fee-for-service (FFS) eligible patients, or “carve out” and purchase drugs for its FFS
…
A federal district judge has allowed five major drugmakers to file friend-of-the-court briefs in a lawsuit over patient eligibility to [...] …